# Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines

> **NCT03911102** · PHASE2 · COMPLETED · sponsor: **Revance Therapeutics, Inc.** · enrollment: 63 (actual)

## Conditions studied

- Lateral Canthal Lines

## Interventions

- **BIOLOGICAL:** DaxibotulinumtoxinA for injection

## Key facts

- **NCT ID:** NCT03911102
- **Lead sponsor:** Revance Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-11
- **Primary completion:** 2020-04-23
- **Final completion:** 2020-04-23
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2023-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03911102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03911102, "Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03911102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*